Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502501 | 0.92 | LMNA (0.43) | LMNAPOLBNR1H4BRD9CTSL | |
| SCHEMBL10785428 | 0.91 | SLC16A3 (0.43) | LMNAPOLBNR1H4BRD9AKT1 | |
| SCHEMBL27718803 | 0.89 | LMNA (0.45) | LMNAPOLBBRD9CTSLAKT1 | |
| SCHEMBL7217624 | 0.88 | NQO2 (0.41) | LMNAPOLBNPSR1BRD9CTSL | |
| SCHEMBL12474847 | 0.88 | POLB (0.42) | LMNAPOLBNR1H4BRD9AKT1 | |
| SCHEMBL15669430 | 0.87 | CTSL (0.43) | LMNAPOLBNPSR1CTSLITGB1 | |
| SCHEMBL1162987 | 0.85 | NR1H4 (0.58) | LMNAPOLBNR1H4BRD9RXFP1 | |
| SCHEMBL5757395 | 0.85 | POLB (0.47) | LMNAPOLBBRD9CTSLAKT1 | |
| SCHEMBL1772002 | 0.85 | LMNA (0.47) | LMNAPOLBNR1H4BRD9CTSL | |
| SCHEMBL30619395 | 0.85 | NR1H4 (0.58) | LMNAPOLBNR1H4BRD9RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| CN-107935988-A | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-105636945-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2017-11-17 | — | — | CN | disclosed |
| EP-2655377-B1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS SA (CH) | 2016-03-30 | — | — | EP | disclosed |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2906581-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| CN-104837858-A | Ketoamide immunoproteasome inhibitors | HOFFMANN LA ROCHE | 2015-08-12 | — | — | CN | disclosed |
| US-8889862-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-11-18 | — | — | US | disclosed |
| WO-2014056748-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| WO-2012085662-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
| US-5830869-A | METALLOPROTEASE INHIBITOR | PHARMACIA & UPJOHN COMPANY | 1998-11-03 | — | — | US | disclosed |
| US-5674864-A | ANALGESICS; ENDOPEPTIDASE AND ENKEPHALINASE INHIBITORS; CARDIOTONIC, PSYCHOTROPIC AND HYPERTENSIVE AGENTS | ROUSSEL UCLAF (FR) | 1997-10-07 | — | — | US | disclosed |
| EP-0796245-A1 | PROCESS FOR THE PREPARATION OF AMIDINO PHENYL PYRROLIDINE $g(b)-ALANINE UREA ANALOGS | G.D. SEARLE & CO. (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5190974-A | Analgesics | ROUSSEL UCLAF (FR) | 1993-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | LMNA 1644/4885POLB 2994/4885NPSR1 3397/4885 |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | LMNA 2576/4885POLB 4795/4885NPSR1 241/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | LMNA 1644/4885POLB 2994/4885NPSR1 3397/4885 |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | LMNA 2309/4885POLB 1457/4885NPSR1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.